Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 13351 - 13375 of 14095 in total

Sarizotan

Investigational
Matched Iupac: … {[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl}({[5-(4-fluorophenyl)pyridin-3-yl]methyl})amine …
Matched Salts cas: … 195068-07-6 …

Ruplizumab

Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
Investigational
Matched Description: … Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of …

SP-420

SP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
Investigational
Matched Iupac: … (4S)-2-{2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl}-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic …
Matched Description: … SP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent …

PH94B

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Matched Description: … It is a member of a new family of pharmaceutical compounds called vomeropherins. ... PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized …

XL418

XL418 is a novel anticancer compound.
Investigational

Dihydroquinidine barbiturate

Experimental

Metandienone

Metandienone is an orally active anabolic androgenic steroid. It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in...
Experimental
Withdrawn
Matched Description: … to be marketed and misused as a performance-enhancing drug in sports. ... It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. ... [A254432] In the US, metandienone is a controlled substance under the Controlled Substances Act. …

NCX 1015

NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Investigational
Matched Description: … NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory …

BG-777

BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Investigational
Matched Description: … BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical …

TAK-751S

TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Matched Description: … TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia …

Ilodecakin

Investigational

Apolizumab

Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.
Investigational

Bivatuzumab

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]
Investigational

Odiparcil

Investigational
Matched Iupac: … 4-methyl-7-{[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxy}-2H-chromen-2-one …

Naratuximab emtansine

Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
Investigational
Matched Description: … Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients …

Tebotelimab

Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
Investigational
Matched Description: … , MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)). ... Tebotelimab is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012 …

GB-13

GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Investigational
Matched Description: … mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A. ... GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered …

CP-39,332

CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency. However, none of the members of this stereoisomers has been marketed.
Experimental
Matched Iupac: … N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine …
Matched Description: … However, none of the members of this stereoisomers has been marketed. ... It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP …

Propanidid

An intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration. (From Martindale, The Extra Pharmacopoeia, 30th ed, p918)
Experimental
Matched Iupac: … propyl 2-{4-[(diethylcarbamoyl)methoxy]-3-methoxyphenyl}acetate …
Matched Description: … anesthesia of short duration. ... An intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of …

Iodine I-125

Iodine I-125 is under investigation in clinical trial NCT00079417 (Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma).
Investigational
Matched Description: … and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma). ... Iodine I-125 is under investigation in clinical trial NCT00079417 (Neoadjuvant Carboplatin and Vincristine …

Diflomotecan

Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).
Investigational
Matched Description: … Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)). ... Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered …

SL017

SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Investigational
Matched Description: … unwanted hair and for treatment of actinic keratosis ... formulated as a topical gel, has been combined with a widely available light source for permanent removal of …

Amelubant

Investigational
Matched Iupac: … ethyl N-(4-{[3-({4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy}methyl)phenyl]methoxy}benzenecarboximidoyl …

Pafuramidine

Pafuramidine, a prodrug of furamidine, currently has orphan status for Pneumocystis jiroveci pneumonia.
Investigational
Matched Iupac: … N-methoxy-4-{5-[4-(N-methoxycarbamimidoyl)phenyl]furan-2-yl}benzene-1-carboximidamide …
Matched Description: … Pafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia …

Darinaparsin

Investigational
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-[(dimethylarsanyl)sulfanyl]ethyl]carbamoyl}butanoic …
Displaying drugs 13351 - 13375 of 14095 in total